High Manganese Content of Lipid NanoMn (LNM) by Microfluidic Technology for Enhancing Anti-Tumor Immunity

Jiawei Sun, Jingjing Gong, Lidong Gong, Chuanda Zhu, L. Liyang, Jingya Wang, Yuanyuan Yang, Shiming Zhang, Silu Liu, Jijun Fu, Pengcheng XuPharmaceutics 2024 · DOI

TL;DR

Researchers have developed a novel manganese-based lipid nanoparticle (LNM) using microfluidics for enhanced anti-tumor immunity. This LNM effectively activates the cGAS-STING pathway, boosts immune responses, and inhibits tumor growth without needing combination chemotherapy, offering a promising, scalable, and safe cancer immunotherapy strategy.

What Problem Does This Paper Address?

Immunotherapy has revolutionized cancer treatment by harnessing the body's own immune system to fight tumors. Manganese ions (Mn²⁺) are known to play a role in boosting anti-tumor immunity by activating the cGAS-STING signaling pathway, which is crucial for initiating immune responses. However, the clinical application of free manganese ions is hampered by their poor cellular uptake and non-specific distribution within the body. While lipid nanoparticles (LNPs) offer a promising delivery system, efficiently producing manganese-loaded LNPs at scale with consistent quality has been a significant challenge. Furthermore, existing manganese-based immunotherapies often require co-administration with chemotherapy drugs or other immune activators to achieve optimal efficacy, limiting their simplicity and potentially increasing side effects. This paper aims to address these limitations by developing a novel manganese lipid nanoparticle (LNM) using microfluidic technology that overcomes the delivery and production challenges, and can elicit a potent anti-tumor immune response independently.

Methods

The core innovation in this study lies in the use of microfluidic technology for the precise and scalable production of the manganese lipid nanoparticles (LNM). The preparation process involves a multi-step microfluidic approach:

  • Microemulsion Formation: A central channel delivers a MnCl₂ solution, while adjacent channels introduce a mixed oil phase (CO-520 and cyclohexane) to form a Mn²⁺ microemulsion. Subsequently, Na₂HPO₄ and the oil phase are introduced to create an HPO₄²⁻ microemulsion.
  • LNM Core Formation: The anionic lipid DOPA is then incorporated to bridge the two microemulsions, forming the manganese phosphate microprecipitate core.
  • Lipid Bilayer Encapsulation: Finally, a lipid film composed of DOTAP, cholesterol, and DSPE-PEG 2000 is formed via thin-film hydration and dispersed to create the outer phospholipid bilayer, encapsulating the LNM core.

The researchers systematically screened and optimized various parameters, including the flow rate ratio (FRR) between aqueous and oil phases, DOPA concentration, and the ratio of the LNM core to the outer phospholipid layer, to achieve optimal particle size, stability, and manganese payload.

Characterization techniques employed include:

  • Transmission Electron Microscopy (TEM) and Scanning Transmission Electron Microscopy (STEM) for morphology and elemental composition.
  • Dynamic Light Scattering (DLS) for particle size and polydispersity index (PDI).
  • Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for intracellular manganese content.
  • Western Blotting to assess the activation of the cGAS-STING pathway.
  • Flow Cytometry for cell uptake and immune cell analysis.
  • ELISA for cytokine level detection.
  • CCK-8 assay for cytotoxicity assessment.
  • In vivo imaging for biodistribution studies.
  • Histological analysis (H&E staining) for safety evaluation.

Datasets

Not discussed in the paper. The study utilizes cell lines (Jurkat, MC38, 3T3, HEF) and animal models (C57BL/6N mice) for experimental validation.

Key Insights and Ideas

  • Microfluidics as a Game-Changer for Nanoparticle Production: The study highlights how microfluidics can overcome the long-standing challenges of producing manganese-based nanoparticles with high payload, stability, and batch-to-batch reproducibility, paving the way for scalable manufacturing.
  • Manganese as a Standalone Immunotherapy Agent: A significant finding is that LNM can effectively activate anti-tumor immunity and inhibit tumor growth without the need for co-administration with chemotherapy drugs or other immune adjuvants, simplifying treatment regimens and potentially reducing side effects.
  • Targeted Immune Activation: LNM demonstrates the ability to activate the cGAS-STING pathway, leading to the production of pro-inflammatory cytokines (IFN-γ and IL-6) and enhancing the activity of crucial immune cells like CD4⁺ and CD8⁺ T cells.
  • Enhanced Cellular Uptake and Tumor Accumulation: LNM exhibits significantly higher cellular uptake compared to free manganese ions and shows preferential accumulation at tumor sites in vivo, improving therapeutic delivery.
  • Excellent Safety Profile: Both in vitro and in vivo studies indicate that LNM possesses a high safety margin, with no significant cytotoxicity or adverse effects on vital organs and biochemical markers.

Key Results

  • Particle Characteristics: The optimized LNM nanoparticles achieved a uniform size of approximately 30-60 nm with good dispersion and high manganese content.
  • Immune Activation: LNM effectively activated the cGAS-STING pathway in cells, leading to increased expression of STING, p-STING, and p-IRF3. In vivo, LNM treatment significantly increased serum levels of IFN-γ and IL-6 and boosted CD4⁺ and CD8⁺ T cell populations.
  • Anti-Tumor Efficacy: In a MC38 tumor-bearing mouse model, LNM treatment significantly inhibited tumor growth and reduced tumor volume and weight compared to control and free MnCl₂ groups, achieving over 60% tumor inhibition.
  • Biodistribution: LNM-DiR showed enhanced accumulation at tumor sites and in the spleen compared to free DiR, with minimal off-target accumulation in other organs.
  • Safety: LNM demonstrated no significant cytotoxicity in 3T3 and HEF cells (IC50 > 100 µM) and showed no adverse effects on body weight, liver/renal function, or organ histology in mice.

Limitations and Future Work

  • In Vivo Efficacy Duration: While the study demonstrates significant anti-tumor effects, the long-term efficacy and optimal dosing schedule for LNM in vivo would benefit from further investigation.
  • Mechanism Refinement: While the cGAS-STING pathway activation is established, further detailed exploration of the precise molecular mechanisms underlying LNM's potent immune activation and tumor inhibition could be beneficial.
  • Clinical Translation: The authors suggest that this microfluidic approach for LNM production opens avenues for widespread application in conventional drug delivery systems, implying future work will focus on translating these findings into clinical settings. This would likely involve more extensive preclinical studies and potentially human trials.

Summary updated

Abstract

Immunotherapy is a clinically effective method for treating tumors. Manganese can activate the cGAS-STING signaling pathway and induce an anti-tumor immune response. However, its efficacy is hindered by non-specific distribution and low uptake rates. In this study, we employed microfluidic technology to design and develop an innovative preparation process, resulting in the creation of a novel manganese lipid nanoparticle (LNM). The lipid manganese nanoparticle produced in this process boasts a high manganese payload, excellent stability, the capacity for large-scale production, and high batch repeatability. LNM has effectively demonstrated the ability to activate the cGAS-STING signaling pathway, induce the production of pro-inflammatory cytokines, and inhibit tumor development. Notably, LNM does not require combination chemotherapy drugs or other immune activators. Therefore, LNM presents a safe, straightforward, and efficient strategy for anti-tumor immune activation, with the potential for scalable production.
BibTeX
@inproceedings{sun2024high,
  author = {Jiawei Sun and Jingjing Gong and Lidong Gong and Chuanda Zhu and L. Liyang and Jingya Wang and Yuanyuan Yang and Shiming Zhang and Silu Liu and Jijun Fu and Pengcheng Xu},
  title = {{High Manganese Content of Lipid NanoMn (LNM) by Microfluidic Technology for Enhancing Anti-Tumor Immunity}},
  booktitle = {Pharmaceutics},
  year = {2024},
  doi = {10.3390/pharmaceutics16040556},
}
Figure